CDEK
← All drugs Report issue

tti-101

Small moleculeexperimental

Clinical trial activity

7 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
5
Phase 3
0
Phase 4
0

Earliest trial started Nov 15, 2017 (NCT03195699)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2023

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05845307Early Phase 1 (Phase 1)Oct 31, 2024National Institutes of Health (NIH), Tvardi Therapeutics, Incorporated, University of Texas at Houston
NCT06141031Phase 1/Phase 2 (Phase 2)Dec 31, 2023Tvardi Therapeutics, Incorporated, University of Colorado, Denver
NCT05668949Phase 1/Phase 2 (Phase 2)Jun 30, 2023Tvardi Therapeutics, Incorporated, University of Texas at Houston
NCT05671835Phase 2May 15, 2023Tvardi Therapeutics, Incorporated
NCT05384119Phase 1/Phase 2 (Phase 2)Nov 30, 2022Tvardi Therapeutics, Incorporated
NCT05440708Phase 1/Phase 2 (Phase 2)Nov 30, 2022Tvardi Therapeutics, Incorporated
NCT03195699Phase 1Nov 15, 2017Tvardi Therapeutics, Incorporated, University of Texas at Houston
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Tvardi Therapeutics, IncorporatedFor profit7422017
University of Texas at HoustonAcademic/Hospital3222017
National Institutes of Health (NIH)Government1012024
University of Colorado, DenverAcademic/Hospital1112023
4 organizations
Page 1 / 1